Trevi Therapeutics (TRVI) Tops Q4 EPS by 2c

Trevi Therapeutics (NASDAQ: TRVI) reported Q4 EPS of ($0.28), $0.02 better than the analyst estimate of ($0.30).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Creatd files Form S-1 and reports Q1 2026 financial results
• Qualcomm investor day to detail data center plans Wednesday